Page 249 - மருத்துவ ரீதியாக ஒருங்கிணைந்த வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Theralase Technologies Inc.: Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ( PDC ) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Virginia Urology ( VU ) has received site Institutional Review Board ( IRB ) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer ( NMIBC ) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin( Study II ). Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval. VU is the first site to receive both central and local site IRB approval. There are 5 additional US clinical study sites that have received central IRB approval and are expected to receive local IRB app

United statesKristina hacheyCalmette guerinVu research departmentTechnologies incTheralase or companyVenture exchangeRegulation services providerTheralase technologies incPhoto dynamic compoundsVirginia urologyInstitutional review boardMuscle invasive bladder cancerClinical studyBacillus calmette guerinUnresponsive carcinoma in situ